Cargando…
Discovery of Pharmaceutical Composition for Prevention and Treatment in Patient-Derived Metastatic Medullary Thyroid Carcinoma Model
Medullary thyroid carcinoma (MTC) is a well-known neuroendocrine carcinoma, derived from C cells of the thyroid gland. Additionally, MTC is an uncommon aggressive carcinoma that metastasizes to lymph nodes, bones, lungs and liver. For MTC, the 10-year general survival ratio of patients with localize...
Autores principales: | Yun, Hyeok-Jun, Lim, Jin-Hong, Kim, Sang-Yong, Kim, Seok-Mo, Park, Ki-Cheong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9405678/ https://www.ncbi.nlm.nih.gov/pubmed/36009450 http://dx.doi.org/10.3390/biomedicines10081901 |
Ejemplares similares
-
Discovery of New Anti-Cancer Agents against Patient-Derived Sorafenib-Resistant Papillary Thyroid Cancer
por: Kim, Yuna, et al.
Publicado: (2023) -
Serum Calcitonin-Negative Medullary Thyroid Carcinoma: A Case Series of 19 Patients in a Single Center
por: Kim, Sun Jung, et al.
Publicado: (2021) -
Vandetanib for the Treatment of Metastatic Medullary Thyroid Cancer
por: Degrauwe, Nils, et al.
Publicado: (2012) -
Cabozantinib for the Treatment of Metastatic Medullary Thyroid Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014) -
Metastatic Lymph Node Ratio for Predicting Recurrence in Medullary Thyroid Cancer
por: Kim, Jinyoung, et al.
Publicado: (2021)